LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.

Authors

Jean-Pascal H. Machiels

Clinique Universitaires St-Luc, Brussels, Belgium

Jean-Pascal H. Machiels , Lisa F. Licitra , Robert I. Haddad , Makoto Tahara , Liz Svensson , Xiuyu Julie Cong , Eva Ehrnrooth , Ezra E. W. Cohen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).

First Author: Ezra E. W. Cohen

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

First Author: Athanassios Argiris

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.

First Author: Barbara Burtness

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).

First Author: Yuki Sato